This product is suitable for use with the?Maxpar? Metal Labeling Kits.?For metal labeling using Maxpar? Ready antibodies,?proceed directly to the step to Partially Reduce the Antibody by adding 100 ?l of Maxpar? Ready antibody to 100 ?l of 4 mM TCEP-R in a 50 kDa filter and continue with the protocol. Always refer to the latest version of Maxpar? User Guide when conjugating Maxpar? Ready antibodies.

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes³. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a⁺ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation^1,3, in vivo and in vitro cell depletion^2,10,15, inhibition of CD8 T cell proliferation³, blocking of cytotoxicity^3,4, immunohistochemical staining^5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)^29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Maxpar? is a registered trademark of Standard BioTools Inc.

1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
8. Kamimura D, et al. 2006. J. Immunol. 177:306.
9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
16. Guo Y, et al. 2008. Blood 112:480. PubMed
17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
29. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
30. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed

1. Jordan S, et al. 2020. Cell. 178(5):1102-1114.e17.. PubMed

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.